Physician profile
John M Spore
NPI 1275540502
$1,795.12
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $121 · 2021: $365 · 2022: $263 · 2023: $200 · 2024: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $396.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $572.80 | 2022-2024 | Puraply, Affinity |
| Intuitive Surgical, INC. | $349.24 | 2019-2021 | |
| Medtronic Vascular, INC. | $252.97 | 2019-2020 | |
| Medtronic, INC. | $113.02 | 2021-2023 | Signia |
| Melinta Therapeutics, LLC | $96.07 | 2019 | |
| Misonix INC | $83.10 | 2019-2021 | |
| Boston Scientific Corporation | $56.27 | 2020-2021 | |
| Kci USA, INC. | $56.24 | 2020-2022 | |
| Smith+Nephew, INC. | $46.62 | 2019-2024 | Pico 7 |
| Davol INC. | $36.35 | 2019 | |
| Integra Lifesciences Corporation | $32.14 | 2020 | |
| Becton, Dickinson and Company | $24.85 | 2019 | |
| Teleflex LLC | $17.38 | 2019 | |
| Zimmer Biomet Holdings, INC. | $17.33 | 2021 | |
| Shire North American Group INC | $16.27 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.16 | 2020 | |
| Z-Medica, LLC | $10.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Spore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.